Abiopharma

Acadia Healthcare to Participate in 44th Annual J.P. Morgan Healthcare Conference

Final approval of ANDA #ANDA #219053 for ACETAMINOPHEN; IBUPROFEN. Decision date: 01/02/2026

New Form 25-NSE - CureVac N.V. Filed: 2026-01-06 AccNo: 0001354457-26-000010 Size: 3 KB

TruBridge, Inc.: TruBridge and The Health Management Academy Launch the Rural Health Collaborative

Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium

New Form D - QHSLab, Inc. Filed: 2026-01-06 AccNo: 0001493152-26-000529 Size: 6 KB

Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon

New Form 25-NSE - Mersana Therapeutics, Inc. Filed: 2026-01-06 AccNo: 0001354457-26-000008 Size: 3 KB

(99% Positive) QHSLab, Inc. (USAQ) Reports Q1 2026 Financial Results

QHSLab (OTCQB:USAQ) Issues Unaudited Financial and Operational Update Ahead of January 2026 Investor Session

📋 Borgeson Blake (Director) plans to sell 220K shares of RECURSION PHARMACEUTICALS, INC. (at $4.36 each, total $959K) Filed: Jan 06, 2026 | ID: 000126

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dark Blue Therapeutics acquired by Amgen for up to $840 million

(85% Positive) DAY ONE BIOPHARMACEUTICALS, INC. (DAWN) Announces Business Combination

(99% Neutral) MERSANA THERAPEUTICS, INC. (MRSN) Announces Business Combination